Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 29 of 43

28 OctOber 2026 Inhalation various mechanisms mentioned above. Depend- ing on the working principle of the nebulizer, the impact on phage viability can vary for each nebulizer and phage type. Table 2 lists the effect of different nebulizer types on phage viability and aerosol per- formance. Carrigy, et al. compared phage nebuliza- tion (phage D29 in saline) using a jet nebulizer (Pari LC Sprint ® , Pari Pharma GmbH, Gräfelfing, Ger- many), a vibrating mesh nebulizer (Aerogen ® Solo, Aerogen, Galway, Ireland) and a soft mist inhaler (Respimat ® , Boehringer Ingelheim, Ingelheim am Nebulized liquid phage suspensions Currently in phage therapy clinical trials, phages are administered as suspensions. However, phages may be unstable in aqueous conditions and undergo degradation of their tails or capsids. Phages in sus- pensions can be stabilized using buffers such as salt- magnesium (SM), Tris or phosphate buffered saline (PBS). Magnesium ions are known to protect phage tails and impart long-term stability [26]. Nebulizers are commonly used for delivering liquid aerosols to the lower airways by generating fine droplets using Nebulizer Phage Type/Titer and Composition Post-Nebulization Aerosol Performance and Lung Deposition Reference Air Jet Nebulizers Pari LC Star Phage D29 2.4 ± 0.3 × 10 9 PFU/mL 4.4 ± 1.1 × 10 5 PFU/mL Delivery rate: 5.4 ± 1.3 × 10 4 PFU/min [27] Multiple phages (BCSR5, SAOMSI, BCSR129, PASA16, Itty13, Maco2, Maco, SeAlphi) 10 9 PFU/mL – 3 mL Reduction fraction from viable/original: SeAlphi – 0.2 log loss, BCSR129 – 2.45 log Maco2 – 2.8 log, Others varied Loss of titer after inhalation varied between phage types [30] Multiple phages (MS2, LPS-5, OMKO-1, TiVP-H6) 10 9 PFU/mL (5 mL) % Recovered: MS2 (10.4%), LPS-5 (22.2%), OMKO-1 (47.3%), TiVP-H6 (14.5%) Fine particle fraction (%): MS2 (77.7%), LPS-5 (52%), OMKO (72.3%), TiVP-H6 (67.8%) [56] SideStream PEV44 (P. aeruginosa) - 4.63 × 10 10 PFU/mL in SM buffer 3.6 ± 2.4 × 10 9 PFU/mL 4.0 ± 2.0% FPF [29] AeroEclipse PELP phage 3 × 10 9 PFU/mL (5 mL) 2.3 × 10 9 PFU/mL 12% FPF [28] Mesh Nebulizers Aeroneb Go (Vibrating mesh) Phage PEV44 (P. aeruginosa) - 4.63 × 10 10 PFU/mL in SM buffer 1.9 ± 0.6 × 10 10 PFU/mL 13.8 ± 7.2% FPF [29] Phage D29 2.3 ± 0.4 × 10 9 PFU/mL 9.0 ± 2.0 × 10 8 PFU/mL Delivery rate: 3.3 ± 0.8 × 10 8 PFU/min [27] Omron NE-U22 (Static mesh) Phage PEV44 (P. aeruginosa) - 4.63 × 10 10 PFU/mL 3.2 ± 0.5 × 10 10 PFU/mL 15.1 ± 5.8% FPF [29] eFlow (Vibrating mesh) Phage KS4-M 2.5 mL suspension with 2.15 ± 1.63 × 10 8 PFU/mL 1.15 ± 0.14 × 10 8 PFU Alveolar phage titer: 2.96 ± 0.29 ×10 8 PFU [57] Soft Mist Inhaler Respimat Phage D29 1.4 ±0.5 × 10 9 PFU/mL 4.0 ± 1.6 × 10 8 PFU/mL Delivery rate: 4.6 ± 2.0 × 10 6 PFU/min [27] FPF: Fine particle fraction PFU: Plaque forming units Pari LC Star ® , Pari Pharma GmbH, Gräfelfing, Germany SideStream ® , Philips Respironics, Amsterdam, The Netherlands AeroEclipse ® , Monaghan Medical Corp., Plattsburgh, New York, US Aeroneb ® Go, Aerogen, Galway, Ireland Omron NE-U22, Omron Healthcare, Kyoto, Japan eFlow ® , Pari Pharma GmbH, Gräfelfing, Germany Respimat ® , Boehringer Ingelheim, Ingelheim am Rhein, Germany Table 2 Aerosol performance of phage liquid suspensions using various devices

Articles in this issue

view archives of Inhalation - INH1026